Osmol is a development stage biopharma company advancing technology licensed from Yale University to prevent chemotherapy induced peripheral neuropathy (CIPN). CIPN is a significant unmet need associated with a number of common chemotherapies including taxanes, the most widely used breast cancer treatment. There are no approved treatments for CIPN, leaving oncologist’s only option to reduce the dose or length of chemotherapy treatment. Osmol’s initial focus is in breast cancer where up to 80% of patients develop CIPN.